Novartis CEO Joe Jimenez passed the microphone to his replacement, Vas Narasimhan, during Wednesday’s fourth-quarter earnings call, and investors got a peek at the incoming chief’s priority list. The public bullet-point list, that is: heavy on the generalities, light on
read moreAs the drug industry took heat in 2017 for “getting away with murder,” among other criticisms, its lobbyists were busy behind the scenes. More: Under fire for pricing and more, PhRMA boosts lobbying spend 30% in 2017 Source: fierce
read moreShire decided to take some production of Cinryze in-house after problems at a contractor last year led to a shortage. The drugmaker said today that with an FDA approval, it will soon start manufacturing the rare disease drug at a site
read moreWith billions on the line between pharma giants Johnson & Johnson and Pfizer, an appeals panel upheld a decision to invalidate a key Remicade patent. More: Johnson & Johnson falls short in a Remicade patent case as star drug slips
read moreKeele, UK-based Cobra Biologics is being handed £2.6 million by Innovate UK to help the firm expand and develop its infrastructure. More: Cobra awarded £2.6m from Innovate UK for expansion Source: News
read moreMylan has launched in the UK the first generic formulation of Teva’s multiple sclerosis blockbuster Copaxone, offering a potentially cheaper alternative for treatment of relapsing forms of the condition. More: Mylan launches Copaxone generic in the UK Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals